Experts from Celltrion have joined the biopharmaceutical research and development company ENcell.
ENcell announced on the 17th that it has established an external cooperation office to strengthen media engagement and shareholder communication following its listing on the KOSDAQ, and has recruited Director Lee Gun-hyuk, who previously worked at Celltrion.
ENcell is developing stem cell therapies for neurogenetic diseases such as Charcot-Marie-Tooth disease, which affect the Samsung family. Group affiliates, including the Samsung Life Public Welfare Foundation, Samsung Life, and Samsung Fire & Marine Insurance, have significantly invested in Eencell.
Director Lee Gun-hyuk worked in various domestic and international financial corporations, including SGI Seoul Guarantee and Lina Life Insurance, before joining the domestic bio corporation Celltrion, where he was responsible for domestic and international media relations. He worked at Celltrion for about eight years starting in 2016, overseeing the promotion of the excellence of key products such as antibody biosimilars and various new drug development projects.
Director Oh Chung-seop, who recently joined as head of strategic planning, also hails from Celltrion. Oh is noted for helping discover promising new business items based on his technical evaluation capabilities while working at Celltrion, significantly contributing to the acquisition of Celltrion’s next-generation drug portfolio. Director Baek Kwang-moon, who joined ENcell in 2021, is also from Celltrion and currently serves as the Deputy Minister of Advanced Biopharmaceuticals GMP.
ENcell CEO Jang Jong-wook said, “We are doing our best to recruit talent to enhance the company’s status and realize our future vision early after listing on the KOSDAQ,” and added, “We will strengthen external communication to accurately convey our differentiated technological capabilities and medium- to long-term growth value to the market, and accelerate the ongoing new drug development efforts.”